Company news
Biote Corp. (NASDAQ:BTMD) news
Every Biote Corp. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
July 22, 2026
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
June 1, 2026
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
May 28, 2026
Biote Reports First Quarter 2026 Financial Results
May 6, 2026
Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
April 22, 2026
Biote Reports Fourth Quarter and Full Year 2025 Financial Results
March 11, 2026
Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
February 25, 2026
Biote Reports Third Quarter 2025 Financial Results
November 5, 2025
Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call
October 22, 2025
Biote Reports Second Quarter 2025 Financial Results
August 6, 2025
Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call
July 23, 2025
Biote Names Rich Barrera to Board of Directors
June 9, 2025
Biote Reports First Quarter 2025 Financial Results
May 7, 2025
Biote Schedules First Quarter 2025 Financial Results Release and Conference Call
April 23, 2025
Biote Announces Purchase of Shares by Directors and CEO
March 18, 2025
Biote Reports Fourth Quarter and Full Year 2024 Financial Results
March 12, 2025
Biote Schedules Fourth Quarter and Full Year 2024 Financial Results Release and Conference Call
February 26, 2025
Biote Announces CEO Retirement and Succession Plan
January 30, 2025
Biote Reports Third Quarter 2024 Financial Results
November 12, 2024
Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call
October 29, 2024
Biote Reports Second Quarter 2024 Financial Results
August 8, 2024
Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call
July 25, 2024
Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares
June 20, 2024
Biote Reports First Quarter 2024 Financial Results
May 7, 2024
Biote Announces Definitive Settlement with Founder
April 29, 2024
Biote Schedules First Quarter 2024 Financial Results Release and Conference Call
April 23, 2024
Biote Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call
February 27, 2024
Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares
February 20, 2024
Biote Announces $20 Million Share Repurchase Authorization
January 25, 2024
Biote Provides Preliminary 2023 Results and Initial 2024 Guidance
January 17, 2024
Biote to Purchase Asteria Health
January 17, 2024
Biote Names Robert Peterson as Chief Financial Officer
January 11, 2024
Biote Reports Third Quarter 2023 Financial Results
November 7, 2023
Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call
October 24, 2023
Biote Reports Second Quarter 2023 Financial Results
August 10, 2023
Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call
July 27, 2023
Biote Formalizes Commitment to Men’s Hormone Health With Launch of New Men’s Health Division
June 22, 2023
Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
June 8, 2023
Biote Announces Pricing of Secondary Offering of Common Stock
June 5, 2023
Biote to Participate at Upcoming Investor Conferences
May 31, 2023
Biote Appoints Mary J. Puncochar as Chief Commercial Officer
May 30, 2023
Biote Reports First Quarter 2023 Financial Results
May 9, 2023
Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
May 9, 2023
Biote Schedules First Quarter 2023 Financial Results Release and Conference Call
April 26, 2023
Biote Names John Denne as General Manager, Men’s Health Division
April 10, 2023
Biote Reports Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023
Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report
March 27, 2023
Biote to Present at 35th Annual Roth Conference
March 2, 2023
Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call
February 9, 2023